{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:34:10Z","timestamp":1770906850489,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.vph.2021.106839","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T07:18:47Z","timestamp":1611991127000},"page":"106839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Exploring the mechanisms of action of gliflozines in heart failure and possible implications in pulmonary hypertension"],"prefix":"10.1016","volume":"138","author":[{"given":"Rosalinda","family":"Madonna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2021.106839_bb0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1242\/dev.132910","article-title":"Building and re-building the heart by cardiomyocyte proliferation","volume":"143","author":"Foglia","year":"2016","journal-title":"Development"},{"key":"10.1016\/j.vph.2021.106839_bb0010","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41569-018-0077-x","article-title":"The interstitium in cardiac repair: role of the immune-stromal cell interplay","volume":"15","author":"Forte","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.vph.2021.106839_bb0015","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2021.106839_bb0020","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2021.106839_bb0025","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.vph.2021.106839_bb0030","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s13300-020-00889-9","article-title":"Are SGLT-2 inhibitors the future of heart failure treatment? The EMPEROR-preserved and EMPEROR-reduced trials","volume":"11","author":"Williams","year":"2020","journal-title":"Diab. Ther"},{"key":"10.1016\/j.vph.2021.106839_bb0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jash.2014.11.001","article-title":"SGLT2 inhibitors: their potential reduction in blood pressure","volume":"9","author":"Maliha","year":"2015","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.vph.2021.106839_bb0040","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13300-018-0385-5","article-title":"Empagliflozin induces transient diuresis without changing long-term overall fluid balance in Japanese patients with type 2 diabetes","volume":"9","author":"Yasui","year":"2018","journal-title":"Diab. Ther"},{"key":"10.1016\/j.vph.2021.106839_bb0045","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2021.106839_bb0050","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0008-6363(03)00468-1","article-title":"The cardiovascular effects of erythropoietin","volume":"59","author":"Smith","year":"2003","journal-title":"Cardiovasc. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.vph.2021.106839_bb0055","article-title":"Sglt-2-inhibition with Dapagliflozin reduces tissue sodium content","volume":"34","author":"Schmieder","year":"2016","journal-title":"J. Hypertens. Suppl."},{"key":"10.1016\/j.vph.2021.106839_bb0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/0003-4819-113-2-155","article-title":"Body fluid volume regulation in health and disease: a unifying hypothesis","volume":"113","author":"Schrier","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.vph.2021.106839_bb0065","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jama.1997.03540330061036","article-title":"Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis","volume":"277","author":"Psaty","year":"1997","journal-title":"JAMA"},{"issue":"Suppl. 2","key":"10.1016\/j.vph.2021.106839_bb0070","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1038\/sj.jhh.1001798","article-title":"The place of diuretics in preventing cardiovascular events","volume":"18","author":"Kaplan","year":"2004","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.vph.2021.106839_bb0075","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10741-019-09860-8","article-title":"Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure","volume":"25","author":"Grosman-Rimon","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.vph.2021.106839_bb0080","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0895-7061(02)02982-5","article-title":"Effect of angiotensin ii receptor blockade on arterial stiffness: beyond blood pressure reduction","volume":"15","author":"Mahmud","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.vph.2021.106839_bb0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/svn-2016-000045","article-title":"Arterial stiffness and stroke: de-stiffening strategy, a therapeutic target for stroke","volume":"2","author":"Chen","year":"2017","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.vph.2021.106839_bb0090","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","article-title":"Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target","volume":"243","author":"Di Franco","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2021.106839_bb0095","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","article-title":"Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart","volume":"467","author":"Vrhovac","year":"2015","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.vph.2021.106839_bb0100","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ihj.2016.06.010","article-title":"Role of cardiac renin angiotensin system in ischemia reperfusion injury and preconditioning of heart","volume":"68","author":"Agrawal","year":"2016","journal-title":"Indian Heart J."},{"key":"10.1016\/j.vph.2021.106839_bb0105","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016270","article-title":"Molecular, cellular, and clinical evidence that sodium-glucose cotransporter 2 inhibitors act as Neurohormonal antagonists when used for the treatment of chronic heart failure","volume":"9","author":"Packer","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.vph.2021.106839_bb0110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00018-013-1349-6","article-title":"The pathogenesis of cardiac fibrosis","volume":"71","author":"Kong","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.vph.2021.106839_bb0115","doi-asserted-by":"crossref","first-page":"10L","DOI":"10.1016\/j.amjcard.2005.09.060","article-title":"Drugs for left ventricular remodeling in heart failure","volume":"96","author":"Frigerio","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.vph.2021.106839_bb0120","doi-asserted-by":"crossref","first-page":"12331","DOI":"10.1111\/jcmm.15699","article-title":"Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes","volume":"24","author":"Madonna","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.vph.2021.106839_bb0125","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","article-title":"Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients","volume":"9","author":"Uthman","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.vph.2021.106839_bb0130","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jacbts.2019.02.006","article-title":"Fibroblasts in the infarcted, Remodeling, and Failing Heart","volume":"4","author":"Humeres","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.vph.2021.106839_bb0135","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/cvr\/cvaa137","article-title":"Stimulating pro-reparative immune responses to prevent adverse cardiac remodelling: consensus document from the joint 2019 meeting of the ESC working groups of cellular biology of the heart and myocardial function","volume":"116","author":"Steffens","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2021.106839_bb0140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/CIRCRESAHA.117.311589","article-title":"Physiologic, pathologic, and therapeutic paracrine modulation of cardiac excitation-contraction coupling","volume":"122","author":"Mayourian","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2021.106839_bb0145","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1016\/j.celrep.2020.02.008","article-title":"Dynamic interstitial cell response during myocardial infarction predicts resilience to rupture in genetically diverse mice","volume":"30","author":"Forte","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.vph.2021.106839_bb0150","doi-asserted-by":"crossref","first-page":"106648","DOI":"10.1016\/j.vph.2020.106648","article-title":"Association of the European Society of cardiology echocardiographic probability grading for pulmonary hypertension with short and mid-term clinical outcomes after heart valve surgery","volume":"125-126","author":"Madonna","year":"2020","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2021.106839_bb0155","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10741-016-9566-3","article-title":"Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure","volume":"21","author":"Ameri","year":"2016","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.vph.2021.106839_bb0160","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1093\/eurheartj\/ehz626","article-title":"The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2021.106839_bb0165","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2174\/1389450116666150722140424","article-title":"Novel strategies in the treatment of pulmonary arterial hypertension","volume":"17","author":"Madonna","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.vph.2021.106839_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9061910","article-title":"Isolated exercise-induced pulmonary hypertension associates with higher cardiovascular risk in scleroderma patients","volume":"9","author":"Madonna","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.vph.2021.106839_bb0175","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1378\/chest.07-1246","article-title":"Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension","volume":"132","author":"Gan","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.vph.2021.106839_bb0180","doi-asserted-by":"crossref","first-page":"14447","DOI":"10.1038\/s41598-018-32784-6","article-title":"Pulmonary artery stiffness by cardiac magnetic resonance imaging predicts major adverse cardiovascular events in patients with chronic obstructive pulmonary disease","volume":"8","author":"Agoston-Coldea","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vph.2021.106839_bb0185","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbrc.2020.01.015","article-title":"The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension","volume":"524","author":"Chowdhury","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.vph.2021.106839_bb0190","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/ehf2.12850","article-title":"Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring","volume":"7","author":"Mullens","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.vph.2021.106839_bb0195","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1186\/s13063-020-04618-2","article-title":"muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial","volume":"21","author":"Lu","year":"2020","journal-title":"Trials"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189121000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189121000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:19:44Z","timestamp":1761527984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189121000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":39,"alternative-id":["S1537189121000112"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2021.106839","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the mechanisms of action of gliflozines in heart failure and possible implications in pulmonary hypertension","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2021.106839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106839"}}